Uncategorized Archives - Page 21 of 134

WednesdaySep 20, 2023 11:15 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Targets Pancreatic Cancer Solution Through Work With GEDI Cube AI Platform, NVIDIA Resources

California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed Renovaro recently announced a binding, exclusive letter of intent (“LOI”) to add GEDI Cube’s artificial intelligence (“AI”) data mining technology to its fight against such cancers GEDI Cube is strengthening its platform’s potential by joining with the NVIDIA Inception program, which nurtures start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists The companies hope to detect pancreatic tumors at early…

WednesdaySep 20, 2023 9:00 am

Generic Drug Manufacturer SOHM, Inc. (SHMN) Building Regenerative Medicine Platform with LOI for Gene Editing Technology

U.S.-based generic drug developer SOHM is working to build its product pipeline through registration for distribution in several states and the planned establishment of its own product manufacturing plant in Southern California SOHM is also focused on developing a regenerative medicine portfolio, having issued an LOI recently in its bid to acquire the gene editing technology ABBIE from CGA Intellectual Holdings Inc. ABBIE is a synthetic enzyme technology that includes a DNA binding solution and a DNA integration solution for introducing a functionally edited genome into an “enhanced” cell that could then be introduced into a patient’s body to repair…

ThursdaySep 14, 2023 9:45 am

Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference

Longeveron management will present at the 25th Annual H.C. Wainwright Global Investment Conference scheduled for September 11-13, 2023, in New York Wa’el Hashad, the company’s CEO, will discuss Longeveron’s cellular therapy programs in a pre-recorded presentation. Both he and Lisa Locklear, EVP & Chief Financial Officer, will be at the conference to discuss the company’s investment strategies and clinical trial progress The company aims to create awareness among scientists and investors of its clinical trial progress, positive clinical results, and cellular therapy programs Longeveron is evaluating its lead investigational product candidate, a cellular product named Lomecel-B(TM), in ongoing clinical trials…

ThursdaySep 14, 2023 9:00 am

Leadership Changes At SOHM, Inc. (SHMN) to Strengthen Growth Strategies for Generic Drug Market and Gene Editing Platform Development

U.S.-based generic drug developer SOHM recently announced the addition of two leading officers — Dr. David Aguilar (Ph.D) as Chief Operating Officer and Dr. Krishna Bhat (MD, Ph.D, FACC) as Chief Medical Advisor The new officers are expected to help direct SOHM’s global growth strategy as the company continues to develop and diversify its product offerings, which include a variety of mediums for administering antibiotics, analgesics, anti-inflammatory and anti-cold therapies, as well as vitamins SOHM also recently announced an LOI to acquire a stem cell disruptive technology and related patents, which include the potential for someday treating damaged hearts via…

ThursdaySep 14, 2023 9:00 am

Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments

Brigham and Women’s Hospital scientists have developed a microdevice to help researchers test the effectiveness of glioma treatments. Gliomas are a type of brain tumor that arise from glial cells in the spinal cord and brain before infiltrating surrounding brain cells. Because the proximity of gliomas to healthy brain cells makes them hard to remove via surgery, glioma treatment often involves removing as much of the tumor via surgery before using chemotherapy or radiation therapy to kill off as many of the remaining cancer cells as possible. Furthermore, researchers find it extremely difficult to test the effects of different drug…

WednesdaySep 13, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica recently announced positive top line results from its PAX-101 Phase 3 African Sleeping Sickness Study, paving the way for an expected New Drug Application filing in 2024 The company granted exclusive pharmacy distribution for PAX-101 to Vox Nova LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with ASD PaxMedica submitted PAX-101 Clinical Trial Request to the South African Health Products Regulatory Authority, requesting approval for a double-blind, placebo-controlled study in ASD The company entered a Research Collaboration Agreement with PoloMar Health and The BRAIN Foundation for a Phase II proof-of-concept trial in ASD PaxMedica (NASDAQ:…

TuesdaySep 12, 2023 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee

About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating psoriasis, may offer significant advantages over Apogee Therapeutics, whose recent IPO has resulted in a $1 billion market cap Scinai’s NanoAbs offer additional routes of administration, a higher affinity and binding to the target, and…

MondaySep 11, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis

RVL Pharmaceuticals' CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year's H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027 RVL Pharmaceuticals (NASDAQ:…

FridaySep 08, 2023 10:30 am

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’

In July 2023, LSDI launched Twilight, a new sleep aid product The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions LSDI in May 2023 launched its new Mindful product line designed to enhance well-being and promote a mindful approach to life Also in May 2023, the company announced a partnership with non-profit TheraPsil to advance medical psilocybin access and research LSDI announced in April 2023 that its board had approved the repurchase of up to 500,000 shares of its Class…

FridaySep 08, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study

CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM 151 patients have been enrolled in the study, marking the data cutoff point and a significant milestone toward reporting topline results before the end of the year Based on the results seen preclinically, the company remains optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Renovaro BioSciences Inc. (NASDAQ: RENB) Targets Pancreatic Cancer Solution Through Work With GEDI Cube AI Platform, NVIDIA Resources

Generic Drug Manufacturer SOHM, Inc. (SHMN) Building Regenerative Medicine Platform with LOI for Gene Editing Technology

Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference

Leadership Changes At SOHM, Inc. (SHMN) to Strengthen Growth Strategies for Generic Drug Market and Gene Editing Platform Development

Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee

RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search